TRENTON, N.J. - The New Jersey federal judge overseeing the Fosamax femur multidistrict litigation on June 17 granted summary judgment in the first post-label-change bellwether case, agreeing with defendant Merck Sharp & Dohme Corp. that the drug's label adequately warned about leg fractures and that the plaintiffs' claims are preempted by federal law (In Re: Fosamax $(Alendronate Sodium$) Products Liability Litigation, MDL Docket No. 2243, No. 08-md-00008, Barbara Gaynor, et al. v. Merck Sharp & Dohme Corp., No. 12-1492, D. N.J.).